Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
G-CHOP vs R-CHOP in previously untreated CD20-positive DLBCL
CTR20130792Phase 3Completed
- Sponsor
- Roche
- Start
- May 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of obinutuzumab in diffuse large B-cell lymphoma (DLBCL), sponsored by Roche. Started May 2014; status: completed.
02
Drugs
obinutuzumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on CTR20130792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20130792.